Metabolic reprogramming via PPARα signaling in cardiac hypertrophy and failure: From metabolomics to epigenetics

被引:46
|
作者
Warren, Junco Shibayama [1 ,2 ]
Oka, Shin-ichi [3 ]
Zablocki, Daniela [3 ]
Sadoshima, Junichi [3 ]
机构
[1] Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA
[2] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA
[3] Rutgers New Jersey Med Sch, Dept Cell Biol & Mol Med, Newark, NJ USA
基金
美国国家卫生研究院;
关键词
fatty acids; deoxyribonucleotide; metabolism; peroxisome proliferator-activated; receptor-alpha; ACTIVATED RECEPTOR-ALPHA; FATTY-ACID-METABOLISM; INDUCED HEART-FAILURE; MITOCHONDRIAL ENERGY-PRODUCTION; THYROID-HORMONE RECEPTOR; GENE-EXPRESSION; CONTRACTILE DYSFUNCTION; PROTEIN-KINASE; TRANSCRIPTION FACTORS; INSULIN-RESISTANCE;
D O I
10.1152/ajpheart.00103.2017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Studies using omicsbased approaches have advanced our knowledge of metabolic remodeling in cardiac hypertrophy and failure. Metabolomic analysis of the failing heart has revealed global changes in mitochondrial substrate metabolism. Peroxisome proliferator-activated receptor-alpha (PPAR alpha) plays a critical role in synergistic regulation of cardiac metabolism through transcriptional control. Metabolic reprogramming via PPAR alpha signaling in heart failure ultimately propagates into myocardial energetics. However, emerging evidence suggests that the expression level of PPAR alpha per se does not always explain the energetic state in the heart. The transcriptional activities of PPAR alpha are dynamic, yet highly coordinated. An additional level of complexity in the PPAR alpha regulatory mechanism arises from its ability to interact with various partners, which ultimately determines the metabolic phenotype of the diseased heart. This review summarizes our current knowledge of the PPAR alpha regulatory mechanisms in cardiac metabolism and the possible role of PPAR alpha in epigenetic modifications in the diseased heart. In addition, we discuss how metabolomics can contribute to a better understanding of the role of PPAR alpha in the progression of cardiac hypertrophy and failure.
引用
收藏
页码:H584 / H596
页数:13
相关论文
共 50 条
  • [41] O-GlcNAc signaling regulates cardiac hypertrophy via NFAT activation
    Facundo, Heberty di Tarso Fernandes
    Brainard, Robert Eli
    Jones, Steven Paul
    FASEB JOURNAL, 2010, 24
  • [42] CHRYSIN AMELIORATES ISOPROTERENOLINDUCED CARDIAC HYPERTROPHY IN RATS VIA MODULATION OF SIGNALING PATHWAYS
    Verma, Vipin Kumar
    Meshram, Sonali
    Arya, Dharamvir Singh
    JOURNAL OF HYPERTENSION, 2023, 41 : E361 - E361
  • [43] The interleukin-1 receptor signaling complex as a potential therapeutic target for the transition from cardiac hypertrophy to failure
    Long, CS
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 69A - 69A
  • [44] Curcumin attenuates cardiomyocyte hypertrophy induced by high glucose and insulin via the PPARγ/Akt/NO signaling pathway
    Chen, Rongchun
    Peng, Xiaofeng
    Du, Weimin
    Wu, Yang
    Huang, Bo
    Xue, Lai
    Wu, Qin
    Qiu, Hongmei
    Jiang, Qingsong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (02) : 235 - 242
  • [45] Summary of the Cologne Conference on Heart Failure: transition from cardiac hypertrophy to failure
    Petra Schnabel
    M. Böhm
    Journal of Molecular Medicine, 1998, 76 : 721 - 722
  • [46] Compartment-specific activation of PPAR governs breast cancer tumor growth, via metabolic reprogramming and symbiosis
    Avena, Paola
    Anselmo, Wanda
    Whitaker-Menezes, Diana
    Wang, Chenguang
    Pestell, Richard G.
    Lamb, Rebecca S.
    Hulit, James
    Casaburi, Ivan
    Ando, Sebastiano
    Martinez-Outschoorn, Ubaldo E.
    Lisanti, Michael P.
    Sotgia, Federica
    CELL CYCLE, 2013, 12 (09) : 1360 - 1370
  • [47] Summary of the Cologne Conference on Heart Failure:: transition from cardiac hypertrophy to failure
    Schnabel, P
    Böhm, M
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (11): : 721 - 722
  • [48] Comprehensive plasma and tissue profiling reveals systemic metabolic alterations in cardiac hypertrophy and failure
    Mueller, Oliver J.
    Heckmann, Markus B.
    Ding, Lin
    Rapti, Kleopatra
    Rangrez, Ashraf Y.
    Gerken, Thomas
    Christiansen, Nicole
    Rennefahrt, Ulrike E. E.
    Witt, Henning
    Maldonado, Sandra Gonzalez
    Ternes, Philipp
    Schwab, Dominic M.
    Ruf, Theresa
    Hille, Susanne
    Remes, Anca
    Jungmann, Andreas
    Weis, Tanja M.
    Kreusser, Julia S.
    Groene, Hermann-Josef
    Backs, Johannes
    Schatz, Philipp
    Katus, Hugo A.
    Frey, Norbert
    CARDIOVASCULAR RESEARCH, 2019, 115 (08) : 1296 - 1305
  • [49] Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
    Caturano, Alfredo
    Vetrano, Erica
    Galiero, Raffaele
    Salvatore, Teresa
    Docimo, Giovanni
    Epifani, Raffaella
    Alfano, Maria
    Sardu, Celestino
    Marfella, Raffaele
    Rinaldi, Luca
    Sasso, Ferdinando Carlo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (05)
  • [50] Changes in cardiac phenotype in hypertrophy and failure: From receptor to gene
    Van Heugten H.A.A.
    Lamers J.M.J.
    Heart Failure Reviews, 1997, 2 (2) : 95 - 106